Recently Approved Pain Relief Devices
.png)
Published: August 2024
Effective pain relief devices are crucial to improve pain outcomes wherin the solutions can be tailored to individual needs, allowing for adjustable intensity and duration of treatment, which enhances patient comfort and effectiveness
We analyzed over 90 pain management device developers that are engaged in developing pain relief devices. In this article, discover recently approved pain relief devices
Acute pain is a type of pain associated with soft tissue damage, such as a strained ankle or a paper cut. It is a physiologic response to an adverse chemical, thermal, or mechanical stimulus, often resulting from surgery, trauma, or acute illness. Acute pain is a consequence of the activation of pain receptors (nociceptors) at the site of tissue damage and typically lasts for less than three to six months. While acute pain is a short-term sensation, chronic pain persists for a longer duration. It is diagnosed as a distinct medical condition, where signals for pain remain active for weeks, months or even years. The International Association for the Study of Pain (IASP) defines chronic pain as a type of pain that has no biological value and persists even after the typical healing duration. Some of the most common chronic pain-related physiological conditions include headache, lower back pain, cancer-related pain, arthritis-related pain and neuropathic pain. According to the AAPM, more than 1.5 billion individuals suffer from chronic pain, globally; of which, 100 million individuals are based in the US. It is worth mentioning that in 2023, more than 50 million adults in the US experienced some form of chronic pain. The prevalence of chronic pain underscores the critical need for effective pain management strategies. Over the years, the field of pain management has seen significant progress, with innovations aimed at better understanding and treating chronic pain conditions.
Pain management devices are popularly used as second-line treatment option for the management of pain and have proven to efficiently relieve muscular and joint-related pains and improve blood circulation. These devices are increasingly being utilized by consumers at home to address chronic pain, typically requiring the consent and guidance of healthcare professionals prior to use. Pain management devices are popularly used as second-line of treatment option for the management of pain and have proven to efficiently relieve muscular and joint-related pains and improve blood circulation. These devices are increasingly being utilized by consumers at home to address chronic pain, typically requiring the consent and guidance of healthcare professionals prior to use. Growing awareness of the risks associated with opioid-use is expected to increase the adoption of these advanced pain management devices, which will complement the pharmacological agents. With such ongoing efforts in this industry, we anticipate that pain management devices hold immense promise as powerful tools for alleviating the pain and improving the lives of patients with chronic pain.
Roots Analysis has conducted an exhaustive study on Pain Management Devices Market featuring the current market landscape and future opportunity for the pain management developers that are engaged in the this pain management devices domain, over a span of 11 years.
Table of Contents
Below, we have listed (in reverse chronological order of approval), the five recently approved pain relief devices.
- Inceptiv™ Closed-Loop Spinal Cord Stimulator
- M-Wave Device
- Proclaim™ DRG Neurostimulation System
- SynchroMed™ III Intrathecal Drug Delivery System
- Proclaim™ SCS family and Eterna SCS platform
Interested in exploring over 90 pain management device developers and recent industry trends?
Discover Below the Details on Recently Approved Pain Relief Devices
Let us deep dive to understand the recently approved pain relief devices (including those approved for other indications) in the pain management devices market. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
With the Approval of Personalized Solution for Chronic Pain, Medtronic Claims to be at the Forefront
1. Inceptiv™ Closed-Loop Spinal Cord Stimulator
In April 2024, Medtronic received the United States Food and Drug Administration (USFDA) approval for Inceptiv device, an implantable closed-loop spinal cord stimulation system, in order to treat chronic pain. Inceptiv is the company’ first pain relief device that offers closed-loop characteristics which can sense the biological signals and simultaneously adjust the stimulation. This supports the device to always provide optimal therapy experience to the patients and avoid any kind of overstimulation. It is worth mentioning that the Inceptiv is the smallest implant that provides 3T magnetic resonance imaging (MRI) access.
Developer’s Details
Medtronic is a US-based firm that is focused on developing innovative diagnostic and therapeutic solutions for more than 70 disease indications. It is interesting to highlight that nearly 72 million patients across 150 countries have reportedly received treatment through a wide array of products offered by the company. Notably, the company has supported nearly 300,000 patients suffering from chronic diseases through its implantable SynchroMed II pumps, worldwide. Additionally, under “Ask a Nurse Program” initiative, the company offers support and guide to patients who are suffering from acute and chronic pain.
Medtronic: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1949 |
| Number of Employees | 10,001+ |
| Headquarter |  |
A brief overview of the pain relief devices being developed by Medtronic has been mentioned in the table below.
Medtronic: Pain Management Devices Portfolio
| Key Parameters | Description |
| Pain Management Devices Offered |
|
| Type of Pain Management Device |
|
| Type of Treatment | Invasive / Minimally Invasive |
| Type of Pain Managed | Chronic Pain |
| Application Area |
|
Further details on pain relief devices developed by Medtronic as well as other pain management device developers have been provided in detail in the report.
Zynex Medical is Focused on Development of Customized Pain Solutions Used in Both Clinical and Home Settings
2. M-Wave Device
In February 2024, Zynex Medical received US FDA approval for its next generation M-Wave neuromuscular electrical stimulation (NMES) device for treatment of patients suffering from chronic pain. Moreover, the device supports enhancement of exercise performance in healthy individuals. M-Wave device has succeeded the E-wave device by being more intuitive and functional.
Developer’s Details
Zynex Medical (a subsidiary of Zynex) is a US-based firm developing innovative medical devices to improve patient care and outcomes. The company specializes in manufacturing electrotherapy products for pain management and rehabilitation. As per the company’s website, it is well-known across the globe for its non-invasive devices, which have been designed to help patients recover from injuries and manage chronic pain. The company's product portfolio also includes electrotherapy devices, compound therapy devices and neurostimulation systems. It is worth highlighting that through its diversified portfolio, the company has served more than one million patients across the globe.
Zynex Medical: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1996 |
| Number of Employees | 501-1,000 |
| Headquarter |  |
A brief overview of the pain relief devices being developed by Zynex Medical has been mentioned in the table below.
Zynex Medical: Pain Management Devices Portfolio
| Key Parameters | Description |
| Pain Management Devices Offered |
|
| Type of Pain Management Device |
|
| Type of Treatment | Non-Invasive |
| Type of Pain Managed |
|
| Application Area |
|
Further details on pain relief devices developed by Zynex Medical as well as other pain management device developers have been provided in detail in the report.
With the Amalgamation of MRI Labeling in the Pain Relief Device, Abbott Envisions to Offer Long-Term Flexibility to the Patients for Imaging Purpose
3. Proclaim™ DRG Neurostimulation System
In January 2024, Abbott received the USFDA approval of expanded magnetic resonance imaging (MRI) labeling for its implantable Proclaim Dorsal Root Ganglion (DRG) stimulation system. Notably, Proclaim DRG system is the first pain relief system based on DRG technology, that provides treatment for complex regional pain syndrome (CRPG) (both type I and type II) pertaining to the lower limbs. The device includes Proclaim platform's Bluetooth® wireless technology, iOS™ software and iPod touch™ mobile digital device patient controller so as to offer an intuitive experience to the patients. It is worth mentioning that the device was initially launched in Europe in January 2017.
Developer’s Details
Abbott is a US-based firm engaged in the development of medical devices, as well as nutritional and branded generic medicines, to cater to the global healthcare needs of patients. The company is engaged in offering innovative solutions in diagnostics, pharmaceuticals, medical devices, and nutritional products. Within the medical device segment, the neuromodulation division is primarily involved in developing next-generation devices for chronic neuropathic pain, Parkinson's disease and essential tremor disorder. It is worth highlighting that the company has launched NeuroSphere myPath digital health app, which provides access to educational resources and tracks real-time data during SCS or DRG devices trial period
Abbott: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 1894 |
| Number of Employees | 10,001+ |
| Headquarter |  |
A brief overview of the pain relief devices being developed by Abbott has been mentioned in the table below.
Abbott: Pain Management Devices Portfolio
| Key Parameters | Description |
| Pain Management Devices Offered |
|
| Type of Pain Management Device |
|
| Type of Treatment | Invasive / Minimally Invasive |
| Type of Pain Managed |
|
| Application Area |
|
Further details on pain relief devices developed by Abbott as well as other pain management device developers have been provided in detail in the report.
Medtronic Strives to Incorporate Advanced Technologies into the Targeted Drug Delivery Therapy for Pain Relief
4. SynchroMed™ III Intrathecal Drug Delivery System
In October 2023, Medtronic received the USFDA approval for SynchroMed III device, a next-generation intrathecal drug delivery device, in order to treat chronic pain, cancer pain and severe spasticity. In comparison to SynchroMed II device, SynchroMed III device encompasses enhanced cybersecurity, efficient programming and capability for any update post the implantation. Moreover, the durable design and “refill-only” work-flow feature supports in achieving targeted drug delivery with better efficacy.
Details on the device developer Medtronic have been covered above.
Abbott Thrives to Develop the Pain Relief Devices that Can Support the Patients Having Limited Treatment Options
5. Proclaim™ SCS family and Eterna SCS platform
In 2023, Abbott received the USFDA approval for its implantable spinal cord stimulation devices in order to treat patients suffering from non-surgical back pain (who have not had / not eligible for corrective surgery). This expansion approval is applicable on both recharge-free Proclaim SCS family and the rechargeable Eterna SCS platform. It is worth mentioning that these devices are based on Abbott's proprietary BurstDR™ SCS technology that provides low-energy stimulation and a battery-life of up to ten years.
Details on the device developer Abbott have been covered above.
What About the Other Pain Relief Devices Around the World?
The above presentation features five recently approved pain relief devices developed by three companies selected from a pool of over 90 industry players that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Sources
- https://news.medtronic.com/2024-04-26-Medtronic-receives-FDA-approval-for-Inceptiv-TM-closed-loop-spinal-cord-stimulator
- https://zynexmed.investorroom.com/2024-02-06-Zynex-Receives-FDA-Clearance-for-its-Next-Generation-NMES-Device.
- https://news.medtronic.com/Medtronic-receives-FDA-approval-for-SynchroMed-TM-III-intrathecal-drug-delivery-system-for-chronic-pain,-cancer-pain,-and-severe-spasticity.